Hypertension and the expanding role of aldosterone

Current Hypertension Reports

Volumn 8, Issue 3, 2006, Pages 255-261

  MacKenzie, Scott M ^b   Connell, John M C ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ANTIHYPERTENSIVE AGENT; EPLERENONE; MINERALOCORTICOID; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; RENIN; SPIRONOLACTONE;

ACUTE HEART INFARCTION; ALDOSTERONE BLOOD LEVEL; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; CYTOSOL; EPITHELIUM CELL; ESSENTIAL HYPERTENSION; HEART FAILURE; HEART MUSCLE FIBROSIS; HORMONAL REGULATION; HORMONE SYNTHESIS; HUMAN; HYPERTENSION; NONHUMAN; PRIMARY HYPERALDOSTERONISM; RECEPTOR BINDING; REVIEW; TARGET CELL; ZONA GLOMERULOSA;

ALDOSTERONE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CLINICAL TRIALS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; RECEPTORS, MINERALOCORTICOID; RENIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 33744951698     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-006-0059-y     Document Type: Review

References (55)

1. Mornet E, Dupont J, Vitek A, White PC: Characterization of two genes encoding human steroid 11beta-hydroxylase (P-450(11) beta). J Biol Chem 1989, 264:20961-20967.
2. Wagner M, Ge Y, Siciliano M, Wells E: A hybrid cell mapping panel for regional localisation of probes to human chromosome 8. Genomics 1991, 10:114-125.
3. Snyder PM, Olson DR, Thomas BC: Serum and glucocorticoid-regulated kinase modulate Nedd4-2 mediated inhibition of the epithelial Na+ channel. J Biol Chem 2002, 277:5-8.
4. Brilla CG, Weber KT: Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992, 120:893-901.
5. Gòmez Sánchez EP: Central hypertensive effects of aldosterone. Front Neuroendocrinol 1997, 18:440-462.
6. Mihailidou AS, Funder JW: Nongenomic effects of mineralocorticoid receptor activation in the cardiovascular system. Steroids 2005, 70:347-351.
7. Haseroth K, Gerdes D, Berger S, et al.: Rapid nongenomic effects of aldosterone in mineralocorticoid-receptor- knockout mice. Biochem Biophys Res Comm 1999, 266:257-261.
8. Romagni P, Rossi F, Guerrini L, et al.: Aldosterone induces contraction of the resistance arteries in man. Atherosclerosis 2003, 166:345-349.
9. Wehling M, Spes CH, Win N, et al.: Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998, 83:3517-3522.
10. Schmidt BM, Montealegre A, Janson CP, et al.: Short-term cardiovascular effects of aldosterone in healthy male volunteers. J Clin Endocrinol Metab 1999, 84:3528-3533.
11. Weber MA, Purdy RE: Catecholamine-mediated constrictor effects of aldosterone on vascular smooth muscle. Life Sci 1982, 30:2009-2017.
12. Yee KM, Struthers AD: Aldosterone blunts the baroreflex response in man. Clin Sci 1998, 95:687-692.
13. Davies E, MacKenzie SM: Extra-adrenal production of corticosteroids. Clin Exper Pharmacol Physiol 2003, 30:437-445.
14. Strömstedt M, Waterman MR: Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain. Brain Res Mol Brain Res 1995, 34:75-88.
15. MacKenzie SM, Clark CJ, Fraser R, et al.: Expression of 11beta-hydroxylase and aldosterone synthase genes in the rat brain. J Mol Endocrinol 2000, 24:321-328.
16. Silvestre JS, Robert V, Heymes C, et al.: Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998, 273:4883-4891.
17. Xue C, Siragy HM: Local renal aldosterone system and its regulation by salt, diabetes and angiotensin II type 1 receptor. Hypertension 2005, 46:1-7.
18. Ye P, Kenyon CJ, MacKenzie SM, et al.: Regulation of aldosterone synthase gene expression in the rat adrenal gland and central nervous system by sodium and angiotensin II. Endocrinology 2003, 144:3321-3328.
19. Agarwal MK, Mirshahi F, Mirshahi M, Rostene W: Immunochemical detection of the mineralocorticoid receptor in rat brain. Neuroendocrinology 1993, 58:575-580.
20. Satoh M, Nakamura M, Saitoh H, et al.: Aldosterone synthase (CYP11B2) expression and myocardial fibrosis in the failing human heart. Clin Sci 2002, 102:381-386.
21. Kayes-Wandover KM, White PC: Steroidogenic enzyme gene expression in the human heart. J Clin Endocrinol Metab 2000, 85:2519-2525.
22. Ye P, Kenyon CJ, MacKenzie SM, et al.: The aldosterone synthase (CYP11B2) and 11β-hydroxylase genes are not expressed in the rat heart. Endocrinology 2005, 146:5287-5293.
23. Gòmez Sánchez EP, Ahmad N, Romero DG, Gòmez Sánchez CE: Origin of aldosterone in the rat heart. Endocrinology 2004, 145:4796-4802.
24. Vasan RS, Evans JC, Larson MG, et al.: Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004, 351:33-41.
25. Schiffrin EL, Franks DJ, Gutkowska J: Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol 1985, 63:1522-1527.
26. Taddei S, Virdis A, Mattei P, Salvetti A: Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension 1993, 21:929-933.
27. Vallotton MB: Primary aldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Clin Endocrinol 1996, 45:47-52.
28. Lifton RP, Dluhy RG, Powers M, et al.: A chimaeric 11β-hydroxylase/ aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992, 355:262-265.
29. White PC, Speiser PW: Steroid 11beta-hydroxylase deficiency and related disorder. Endocrinol Metabol Clin North Am 1994, 23:325-339.
30. Connell JM, Fraser R, MacKenzie SM, Davies E: Is altered adrenal steroid synthesis a key intermediate phenotype in hypertension? Hypertension 2003, 41:993-999.
31. Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exper Pharmacol Physiol 1994, 21:315-318.
32. Lim PO, Rodgers P, Cardale K, et al.: Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 1999, 353:40.
33. Fardella CE, Mosso L, Gòmez Sánchez CE, et al.: Primary aldosteronism in essential hypertensives: prevalence, biochemical profile and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
34. Young WF Jr: Primary aldosteronism: update on diagnosis and treatment. Endocrinologist 1997, 7:213-221.
35. Lim PO, MacDonald TM, Holloway CD, et al.: Variation at the aldosterone synthase (CYP11B2) locus contributes to hypertension in subjects with a raised aldosterone to renin ratio. J Clin Endocrinol Metab 2002, 87:4398-4402.
36. Davies E, Holloway CD, Ingram MC, et al.: Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2 Hypertension 1999, 33:703-707.
37. Paillard F, Chansel D, Brand E, et al.: Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension 1999, 34:423-429.
38. Mulatero P, Schiavone D, Fallo F, et al.: CYP11B2 gene polymorphisms in idiopathic hyperaldosteronism. Hypertension 2000, 35:694-698.
39. Bassett MH, Zhang Y, Clyne C, et al.: Differential regulation of aldosterone synthase and 11β-hydroxylase transcription by steroidogenic factor-1. J Mol Endocrinol 2002, 28:125-135.
40. de Simone G, Tommaselli A, Rossi R, et al.: Partial deficiency of adrenal 11β-hydroxylase - a possible cause of primary hypertension. Hypertension 1985, 7:204-210.
41. Connell JM, Jamieson A, Davies E, et al.: 11beta-hydroxylase activity in glucocorticoid suppressible hyperaldosteronism: Lessons for essential hypertension? Endocr Res 1996, 22:691-700.
42. Davies E, Holloway CD, Ingram MC, et al.: An influence of variation in the aldosterone synthase gene (CYP11B2) on corticosteroid responses to ACTH in normal human subjects. Clin Endocrinol 2001, 54:813-817.
43. Kennon B, Ingram MC, Friel EC, et al.: Aldosterone synthase gene variation and adrenocortical response to sodium status, angiotensin II and ACTH in normal male subjects. Clin Endocrinol 2004, 61:174-181.
44. Hautanen A, Raikkonen K, Adlercreutz H: Associations between pituitary-adrenocortical function and abdominal obesity, hyperinsulinaemia and dyslipidaemia in normotensive males. J Intern Med 1997, 241:451-461.
45. Whitworth JA, Mangos GJ, Kelly JJ: Cushing, cortisol and cardiovascular disease. Hypertension 2000, 36:912-916.
46. Inglis GC, Plouin PF, Friel EC, et al.: Polymorphic differences from normal in the aldosterone synthase gene (CYP11B2) inpatients with primary hyperaldosteronism and adrenal tumour (Conn's syndrome). Clin Endocrinol 2001, 54:725-730.
47. Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243-1248.
48. Pitt B, Zannad F, Remme WJ, et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717.
49. Pitt B, Remme W, Zannad F, et al.: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
50. Young M, Funder JW: Eplerenone, but not steroid withdrawal, reverses cardiac fibrosis in deoxycorticosterone/salt-treated rats. Endocrinology 2004, 145:3153-3157.
51. Komiya I, Yamada T, Takasu N, et al.: An abnormal sodium metabolism in Japanese patients with essential hypertension, judged by serum sodium distribution, renal function and the renin-aldosterone system. J Hypertens 15:65-72.
52. Lim PO, Dow E, Brennan G, et al.: High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14:311-315.
53. Loh K, Koay ES, Khaw MC, et al.: Prevalence of primary aldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 85:2854-2859.
54. Rayner BL, Opie LH, Davidson JS: The aldosterone/renin ratio as a screening test for primary aldosteronism. S Afr Med J 90:394-400.
55. Rossi E, Regolisti G, Negro A, et al.: High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15:896-902.